Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01369966
View directory record Official record
Conditions
Schizophrenia, Smoking Cessation, Nicotine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 62 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 15, 2026, 5:33 AM EDT
Not yet recruiting Phase 4 Interventional

Bromocriptine for Patients With Schizophrenia and Prediabetes

NCT03575000
View directory record Official record
Conditions
Schizophrenia, PreDiabetes
Interventions
Bromocriptine
Drug
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 15, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

NCT06058702
View directory record Official record
Conditions
Schizophrenia, Cannabis Use Disorder
Interventions
Delta-9-THC Very Low Dose, Placebo, Delta-9-THC Medium Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis

NCT02398292
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
M3 Program, Control
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 25 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

NCT03208036
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
Interventions
TDCS, Sham Stimulation, Cognitive Remediation, Bridging Group
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Song-making In a Group (SING)

NCT05929352
View directory record Official record
Conditions
Schizophrenia
Interventions
Musical Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia

NCT01010477
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Nicotine Nasal Spray, Behavioral counseling
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Social Cognition Assessment in Young Adults

NCT02922400
View directory record Official record
Conditions
Cognitive Function 1, Social
Interventions
Social Cognition Assessment and Training
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
17 Years to 40 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional

A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis

NCT01399112
View directory record Official record
Conditions
Smoking, Psychosis
Interventions
Web-based computer program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

NCT00809770
View directory record Official record
Conditions
Drug Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management, Non Contingent Control Condition
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCT00373672
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
armodafinil (Nuvigil), placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia

NCT00936351
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Mindfulness Meditation, Support Group (control)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

NCT03859973
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 15, 2026, 5:33 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mechanisms of Cognitive Change

NCT04103775
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive Remediation, Active Control
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
15 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

NCT02411695
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole (OPC-34712)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Little Rock, Arkansas • Culver City, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional

A System for Preference Assessment in Mental Health

NCT02183844
View directory record Official record
Conditions
Mental Disorders, Schizophrenia, Overweight, Obesity
Interventions
Psychosocial Weight Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Not applicable Interventional Results available

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

NCT01242371
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Probiotic Supplement, Identical-appearing Placebo
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 15, 2026, 5:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Knowledge and Perception of Smoking Risks/Consequences

NCT00686101
View directory record Official record
Conditions
Cigarette Smoking, Schizophrenia
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 15, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
View directory record Official record
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 15, 2026, 5:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
PET
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:33 AM EDT